UA73726C2 - - Google Patents

Download PDF

Info

Publication number: UA73726C2
Authority: UA; Ukraine
Prior art keywords: differs; bronchodilator; heparin; sulfated polysaccharide; inhalation
Prior art date: 1998-10-30

Application number

UA2001042960A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Baker Norton Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-30

Filing date

1999-10-13

Publication date

2005-09-15

1999-10-13 Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma

1999-10-13 Priority claimed from PCT/US1999/024034 external-priority patent/WO2000025723A2/en

2005-09-15 Publication of UA73726C2 publication Critical patent/UA73726C2/uk

Links

239000000203 mixture Substances 0.000 claims abstract description 77
238000000034 method Methods 0.000 claims abstract description 68
229940124630 bronchodilator Drugs 0.000 claims abstract description 67
239000000048 adrenergic agonist Substances 0.000 claims abstract description 15
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 57
229920000669 heparin Polymers 0.000 claims description 54
208000006673 asthma Diseases 0.000 claims description 52
229960002897 heparin Drugs 0.000 claims description 51
238000011282 treatment Methods 0.000 claims description 36
241000124008 Mammalia Species 0.000 claims description 23
230000007170 pathology Effects 0.000 claims description 21
150000004676 glycans Chemical class 0.000 claims description 19
229920001282 polysaccharide Polymers 0.000 claims description 18
239000005017 polysaccharide Substances 0.000 claims description 18
239000000843 powder Substances 0.000 claims description 16
239000003055 low molecular weight heparin Substances 0.000 claims description 12
229940127215 low-molecular weight heparin Drugs 0.000 claims description 12
239000000443 aerosol Substances 0.000 claims description 10
239000000808 adrenergic beta-agonist Substances 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 5
230000014508 negative regulation of coagulation Effects 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 3
150000004044 tetrasaccharides Chemical class 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 4
229960004017 salmeterol Drugs 0.000 claims 4
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 2
HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 2
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 2
239000000695 adrenergic alpha-agonist Substances 0.000 claims 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
229960003060 bambuterol Drugs 0.000 claims 2
ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims 2
229960004620 bitolterol Drugs 0.000 claims 2
FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 claims 2
229960002848 formoterol Drugs 0.000 claims 2
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
229960001268 isoetarine Drugs 0.000 claims 2
229940039009 isoproterenol Drugs 0.000 claims 2
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 2
229960002657 orciprenaline Drugs 0.000 claims 2
229960005414 pirbuterol Drugs 0.000 claims 2
229960002052 salbutamol Drugs 0.000 claims 2
229960000195 terbutaline Drugs 0.000 claims 2
239000000168 bronchodilator agent Substances 0.000 abstract description 31
230000001225 therapeutic effect Effects 0.000 abstract description 5
239000012636 effector Substances 0.000 description 50
229960002329 methacholine Drugs 0.000 description 20
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 16
230000037396 body weight Effects 0.000 description 14
239000003814 drug Substances 0.000 description 14
230000000694 effects Effects 0.000 description 14
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
239000004480 active ingredient Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000000556 agonist Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000007788 liquid Substances 0.000 description 11
238000013459 approach Methods 0.000 description 10
229940068196 placebo Drugs 0.000 description 10
239000000902 placebo Substances 0.000 description 10
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
230000000178 bronchoprotective effect Effects 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
238000011161 development Methods 0.000 description 8
230000004044 response Effects 0.000 description 8
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
206010006482 Bronchospasm Diseases 0.000 description 7
239000000463 material Substances 0.000 description 7
229920002683 Glycosaminoglycan Polymers 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000007423 decrease Effects 0.000 description 6
239000002565 heparin fraction Substances 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
239000002253 acid Substances 0.000 description 5
210000000621 bronchi Anatomy 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
150000002482 oligosaccharides Polymers 0.000 description 5
230000026731 phosphorylation Effects 0.000 description 5
238000006366 phosphorylation reaction Methods 0.000 description 5
208000009079 Bronchial Spasm Diseases 0.000 description 4
208000014181 Bronchial disease Diseases 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
108010073385 Fibrin Proteins 0.000 description 4
102100040959 Tyrosine-protein kinase FRK Human genes 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
229960001334 corticosteroids Drugs 0.000 description 4
238000000586 desensitisation Methods 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
-1 for example Polymers 0.000 description 4
239000007789 gas Substances 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
210000003630 histaminocyte Anatomy 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
229920001542 oligosaccharide Polymers 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
210000002345 respiratory system Anatomy 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
229960000278 theophylline Drugs 0.000 description 4
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
108010022901 Heparin Lyase Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000004479 aerosol dispenser Substances 0.000 description 3
239000013566 allergen Substances 0.000 description 3
102000012740 beta Adrenergic Receptors Human genes 0.000 description 3
108010079452 beta Adrenergic Receptors Proteins 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000000812 cholinergic antagonist Substances 0.000 description 3
229960000265 cromoglicic acid Drugs 0.000 description 3
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000002634 heparin fragment Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000002085 irritant Substances 0.000 description 3
231100000021 irritant Toxicity 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
239000006199 nebulizer Substances 0.000 description 3
239000002831 pharmacologic agent Substances 0.000 description 3
229920000447 polyanionic polymer Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 2
108060003345 Adrenergic Receptor Proteins 0.000 description 2
102000017910 Adrenergic receptor Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
208000005392 Spasm Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
208000037883 airway inflammation Diseases 0.000 description 2
230000003385 bacteriostatic effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
230000007885 bronchoconstriction Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
238000005266 casting Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229960000610 enoxaparin Drugs 0.000 description 2
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
150000002826 nitrites Chemical class 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000003825 pressing Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
235000002020 sage Nutrition 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000005670 sulfation reaction Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
101710117545 C protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000402754 Erythranthe moschata Species 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
210000005058 airway cell Anatomy 0.000 description 1
230000010085 airway hyperresponsiveness Effects 0.000 description 1
229960004784 allergens Drugs 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127090 anticoagulant agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229940127225 asthma medication Drugs 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
210000003123 bronchiole Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004941 influx Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000013123 lung function test Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000010517 secondary reaction Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000000779 smoke Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000003506 spasmogen Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000013638 trimer Substances 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA2001042960A 1998-10-30 1999-10-13 UA73726C2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10650798P	1998-10-30	1998-10-30
PCT/US1999/024034 WO2000025723A2 (en)	1998-10-30	1999-10-13	Methods and compositions for the prevention of tolerance to medications

Publications (1)

Publication Number	Publication Date
UA73726C2 true UA73726C2 (hu)	2005-09-15

Family

ID=27804349

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001042960A UA73726C2 (hu)	1998-10-30	1999-10-13

Country Status (3)

Country	Link
RU (1)	RU2226103C2 (hu)
UA (1)	UA73726C2 (hu)
ZA (1)	ZA200103375B (hu)

1999
- 1999-10-13 RU RU2001114522/14A patent/RU2226103C2/ru not_active IP Right Cessation
- 1999-10-13 UA UA2001042960A patent/UA73726C2/uk unknown
2001
- 2001-04-25 ZA ZA200103375A patent/ZA200103375B/en unknown

Also Published As

Publication number	Publication date
RU2226103C2 (ru)	2004-03-27
ZA200103375B (en)	2003-02-06

Publication	Publication Date	Title
AU760119B2 (en)	2003-05-08	Methods and compositions for the prevention of tolerance to medications
US5980865A (en)	1999-11-09	Method for treating late phase allergic reactions and inflammatory diseases
JP3263723B2 (ja)	2002-03-11	喘息を治療するための組成物、及び喘息にかかった患者を治療するための気管支内薬物の製造における超低分子量ヘパリンの使用
EP0756486A1 (en)	1997-02-05	Pharmaceutical inhalation compositions containing a solid active ingredient
UA73726C2 (hu)	2005-09-15
KR20040008157A (ko)	2004-01-28	염증을 치료하기 위한 과황산화 이당류 및 이를 이용한 방법
EP1462148A2 (en)	2004-09-29	Methods and compositions for the prevention of tolerance to bronchodilators
AU775161B2 (en)	2004-07-22	Method and compositions for treating late phase allergic reactions and inflammatory diseases
RU2179445C2 (ru)	2002-02-20	Способ и композиция для лечения астмы
MXPA98001165A (en)	1998-11-09	Method and composition for the treatment of the
MXPA00000992A (en)	2001-05-07	Method and compositions for treating late phase allergic reactions and inflammatory diseases
CZ2000426A3 (cs)	2001-02-14	Farmaceutický přípravek k léčení pozdní fáze alergické reakce a zánětlivé nemoci